Biocon Ltd. — Regulatory Filings 2020

Nov 21, 2020

==> picture [132 x 52] intentionally omitted <==

Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417

www.biocon.com

November 21, 2020

To The Manager BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street,Mumbai – 400 001	To The Manager, National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
Scrip Code – 532523	Scrip Symbol - Biocon

Subject: Disclosure of Related Party Transactions pursuant to Regulation 23(9) of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 (“SEBI Listing Regulation”)

Dear Sir/Madam,

In compliance with Regulation 23(9) of SEBI Listing Regulations, please find enclosed disclosure of related party transactions on consolidated basis for the half year ended September 30, 2020, drawn in accordance with applicable accounting standard.

The above information will also be available on the website of the company at www.biocon.com.

Kindly take on record the above information and acknowledge.

Thanking You,

Yours faithfully,

==> picture [77 x 81] intentionally omitted <==

For Biocon Limited

==> picture [97 x 36] intentionally omitted <==

___ Mayank Verma Company Secretary and Compliance Officer

Disclosure of related party transactions- On consolidated basis In pursuance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulation, 2018 (All amounts are in Indian Rupees Million)

List of related parties with whom the Group had transactions during the period:

==> picture [443 x 292] intentionally omitted <==

----- Start of picture text -----

Name of related parties Nature of relationship
Key management personnel
Kiran Mazumdar-Shaw Exceutive Chairperson
Siddharth Mittal Managing Director & CEO
Anupam Jindal Chief Financial Officer (w.e.f September 22, 2020)
Indranil Sen Chief Financial Officer (Interim) (w.e.f May 15, 2020 - upto September 22, 2020)
Mayank Verma Company Secretary
Daniel M Bradbury Independent director
Mary Harney Independent director
Vijay K Kuchroo Independent director
M Damodaran Independent director
Bobby K Parikh Independent director
John Shaw Non-executive director
Ravi Mazumdar Non-executive director
Joint Ventures
NeoBiocon FZ LLC Joint-venture
Other related parties
Biocon Foundation Trust in which key management personnel are the Board of Trustees
Immuneel Therapeutics Private Limited Enterprise in which a director of the Company is a shareholder
Mazumdar Shaw Medical Foundation Trust in which key management personnel are the Board of Trustees
Glentec International Limited Enterprise owned by key management personnel
Catherine Rosenberg Relative of a director
Clarie Mazumdar Relative of a director
Jeeves Enterprise in which relative to a director of the Company is proprietor
Narayana Hrudayalaya Limited Enterprise in which a director of the Company is a member of board of directors
----- End of picture text -----

The Group has the following related party transactions

		Half year ended	Half year ended
		September	30,
Particulars	Transactions / Balances	2020
Key management personnel	Salary and perquisites [refer note (a) & (b) below]		55
	Sitting fees and commission		17
	Outstanding as at the period end:
	- Trade and other payables		4
Joint Venture	Purchase of goods		258
	Sales promotion expenses		17
	Expenses incurred on behalf of the related party		*
	Outstanding as at the period end:
	- Trade and other receivables		5
	- Trade and other payables		595
Other related parties	Sale of goods		22
	Sale of services		1
	Salary and perquisites (includes sitting fees)		24
	Health services availed		1
	CSR Expenditure		14
	Other expenses		21
	Outstanding as at the period end:
	- Trade and other receivables		21
	- Trade and other payables		16

• Amounts are not represented since the amounts are rounded off to Rupees million.

(a) The remuneration to key managerial personnel does not include the provisions made for gratuity and compensated absences, as they are obtained on an actuarial basis for the Company as a whole.

(b) Share-based compensation expense allocable to key management personnel is Rs 37 which is not included in the remuneration disclosed above.

(c) The above disclosures include related parties as per Ind AS 24 on "Related Party Disclosures" and Companies Act, 2013.

(d) All transactions with these related parties are priced on an arms length basis and none of the balances are secured.